التفاصيل البيبلوغرافية
| العنوان: |
Farnesyltransferase (FTase) Inhibitors Increase Inhibition of KIT Mutants by Imatinib. |
| المؤلفون: |
Zhaoyang Fan, Liangying Zhang, Shaoting Zhang, Anbu Liu, Shujing Li, Xu Cao, Jinhai Tian, Sien Zhao, Jianmin Sun |
| المصدر: |
Reports of Biochemistry & Molecular Biology; Apr2023, Vol. 12 Issue 1, p74-82, 9p |
| مصطلحات موضوعية: |
GASTROINTESTINAL stromal tumors, RAS oncogenes, CELL transformation, IMATINIB, PROTEIN-tyrosine kinases, CELL survival |
| مستخلص: |
Background: Mutations in the receptor tyrosine kinase KIT are the major cause of gastrointestinal stromal tumors. KIT-mediated activation of the RAS/RAF/MEK/ERK and PI3 kinase/AKT pathways plays an important role in KIT mutant-mediated cell transformation. Methods: The frequently seen primary KIT mutations W557K558del and V560D, and the secondary KIT mutations V654A and N822K, in gastrointestinal stromal tumors were stably transfected into Ba/F3 cells. Cell proliferation was examined with a CCK kit, and cell survival and cell cycle were examined by flow cytometry. Cell signaling was examined by western blot. Results: We found that farnesyltransferase inhibitors tipifarnib and lonafarnib, which inhibit RAS activity, inhibited ERK activation mediated by both wild-type and KIT mutants, which often occur in gastrointestinal stromal tumors. Correspondingly, both wild-type and KIT mutant-mediated cell survival and proliferation were inhibited by both inhibitors. Imatinib is used as the first-line targeted therapy for gastrointestinal stromal tumors in the clinic. In our study, both inhibitors increased imatinib-mediated inhibition of cell survival and proliferation induced by both wild-type and KIT mutants. Similar to the primary KIT mutations, secondary mutations of KIT-induced ERK activation and cell response were inhibited by both inhibitors. Conclusions: Our results suggested the potential benefit of farnesyltransferase inhibitors either alone or combined with imatinib in the treatment of gastrointestinal stromal tumors carrying KIT mutations. [ABSTRACT FROM AUTHOR] |
|
Copyright of Reports of Biochemistry & Molecular Biology is the property of Varastegan Institute for Medical Sciences and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder